Integra LifeSciences Holdings Corp. 8-K Summary
Business Context and Reporting Period
Integra LifeSciences Holdings Corporation (Nasdaq: IART) filed a Current Report on Form 8-K on July 29, 2026, to announce financial results for the quarter ended June 30, 2026. The filing incorporates by reference a press release (Exhibit 99.1) containing detailed financial data and reconciliations of GAAP to non-GAAP measures.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Instead, it outlines the methodology for the following non-GAAP measures included in the attached press release:
- Organic Revenues: Total revenues excluding currency exchange effects, current-period acquisitions, and product divestitures.
- Adjusted EBITDA: GAAP net income adjusted for depreciation, amortization, interest, taxes, impairment charges, and specific operating expenses.
- Adjusted Net Income: GAAP net income excluding structural optimization, M&A integration, EU Medical Device Regulation (MDR) compliance, Braintree facility transition, intangible asset amortization, tax impacts, and impairments.
- Net Debt: GAAP total debt (excluding deferred financing costs) less short-term investments, cash, and cash equivalents.
Material Changes and Adjustments
The filing details specific items excluded from adjusted financial measures to facilitate period-to-period comparability:
- Structural Optimization: Severance and facility exit costs related to rationalization and efficiency improvements.
- M&A Activity: Costs related to acquisitions, divestitures, and integration, including inventory fair value adjustments and contingent consideration changes.
- Regulatory and Operational Transitions: Costs associated with EU MDR compliance and the transition of manufacturing operations from Boston to Braintree, Massachusetts.
- Impairment Charges: Goodwill impairments driven by tariff-related economic uncertainty and quality/supply issues impacting market capitalization.
Guidance, Outlook, and Risks
Management provided forward-looking guidance for organic revenues and adjusted earnings per diluted share but explicitly declined to provide reconciliations to forward-looking GAAP measures. This is due to the high variability of foreign exchange rates and certain GAAP expense items, which management cannot predict with reasonable certainty.
Risks and Contingencies:
- Foreign Exchange: Significant revenue generation in foreign currencies creates volatility in reported results.
- Regulatory Compliance: Ongoing costs related to EU Medical Device Regulations.
- Operational Transitions: Risks associated with the Braintree manufacturing transition.
- Market Conditions: Tariff changes and economic uncertainty have contributed to goodwill impairments.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific numerical values of GAAP and non-GAAP results for the quarter ended June 30, 2026.
- Verify the magnitude of goodwill impairment charges and their specific drivers (tariffs, quality issues).
- Assess the impact of foreign exchange rates on the difference between GAAP and organic revenue growth.
- Examine the reconciliation tables to understand the tax impact of non-GAAP adjustments.
- Confirm the status and cost implications of the Braintree manufacturing transition.